An update of the current pharmacotherapeutic armamentarium for hemophilia A-Reference-Cited by-同舟云学术

An update of the current pharmacotherapeutic armamentarium for hemophilia A

Published:2021-08-18 Issue:1 Volume:23 Page:129-138
ISSN:1465-6566
Container-title:Expert Opinion on Pharmacotherapy
language:en
Short-container-title:Expert Opinion on Pharmacotherapy

Author:

Mahlangu Johnny¹

Affiliation:

1. Department of Molecular Medicine and Haematology, Faculty of Health Sciences, University of the Witwatersrand and NHLS, Parktown, South Africa

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Pharmacology,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/14656566.2021.1961742

Reference95 articles.

1. World Federation of Haemophilia. 2019 Annual global survey: World Federation of Haemophilia. [Last Accessed 2021 Jan 06]. Available at https://www.wfh.org/en/our-work-research-data/annual-global-survey

2. Emerging therapies for haemophilia - Global perspective

3. The evolution of recombinant factor replacement for hemophilia

4. Long-Term Safety and Efficacy Data of a Plasma-Derived Factor VIII Concentrate with von Willebrand Factor for Treatment of Patients with Hemophilia A Covering 18 Years

5. The current and future role of plasma-derived clotting factor concentrate in the treatment of haemophilia A

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Emicizumab and unmet needs of patients with hemophilia a who are managed with replacement therapies;Expert Review of Hematology;2024-09-12

2. Diagnosis and treatment challenges in lower resource countries: State‐of‐the‐art;Haemophilia;2024-03-10

3. Reduced FVIII recovery associated with anti-FVIII PEG antibodies after BNT162b2 SARS-CoV-2 vaccination;Blood Advances;2023-01-10

4. Prophylaxis is the new standard of care in patients with haemophilia;South African Medical Journal;2022-06-01

5. Emicizumab state‐of‐the‐art update;Haemophilia;2022-05